compname reports $5,900,000 for third quarter 2020 performance and earnings.
compname reports q2 earnings per share $0.22.
q2 sales rose 4.1% to $917.7 million.
q2 revenues $737.7 million versus refinitiv ibes estimate of $712.5 million.
raises q2 gaap earnings per share view to $2.61 to $3.19.
compname reports third quarter 2021 results, including a decline in its industrial businesses due to global economic uncertainty.
q2 international revenue $180.1 million versus refinitiv ibes estimate of $178.9 million.
qtrly net sales and operating profit per share decreased 2.7% when adjusted for foreign exchange, acquisitions and divestitures.
expect international growth rates to be negatively impacted in q2 by exiting medical care contracts and manufacturing and industrial services.
q2 revenue $8.6 million versus refinitiv ibes estimate of $7.0 billion.
q3 gross profit $381.8 million versus refinitiv ibes estimate of $289.6 million.
q2 adjusted non-gaap earnings per share $198.7 excluding items.
q4 adjusted earnings per share $183.1 from operations/ebita $0.75.
q4 net interest expense $23.7 million versus refinitiv ibes estimate of $23-$24.7 mln.
q2 adjusted non-gaap income tax rate of 33.8%.
q4 loss per share $1.74.
